DEF: Owens & Minor Sets Date for 2025 Annual Meeting, Outlines Executive Compensation and Governance Practices

Owens & Minor announces its 2025 Annual Meeting of Shareholders to be held virtually on May 15, 2025, detailing proposals for director elections, auditor ratification, and executive compensation approval.

Summary

• Owens & Minor will hold its Annual Meeting of Shareholders virtually on May 15, 2025.
• Shareholders of record as of March 19, 2025, are entitled to vote on the election of nine directors, ratification of KPMG LLP as the independent auditor, and an advisory vote on executive compensation.
• The Board recommends voting for all director nominees, ratification of KPMG, and approval of executive compensation.
• The document details corporate governance practices, including director independence, board leadership structure, and risk oversight.
• Executive compensation is designed to align with company strategy and goals, with a focus on performance-based incentives.
• The document includes information on director and executive compensation, stock ownership, and potential payments upon termination or change in control.
• The company's ESG framework focuses on environmental stewardship, customer and community care, responsible operations, and teammate empowerment.
• The Governance & Nominating Committee oversees ESG programs and practices.
• The company's executive compensation program is designed to reward executive leaders for company and individual performance.
• The company's executive compensation program is designed to enhance both shortand long-term performance.

Sentiment

Score: 7

Explanation: The document is largely factual and informative, outlining governance and compensation practices. The positive financial results and shareholder support contribute to a moderately positive sentiment.

Positives

• High shareholder support for executive compensation in the 2024 advisory vote, with approximately 98% approval.
• The company has a recoupment policy in place to recover incentive compensation and all time-vesting equity awards under certain circumstances.
• The company prohibits hedging and pledging of company stock by executive officers and directors.
• The company has stock ownership guidelines for its directors and executive officers.
• The company's ESG framework focuses on environmental stewardship, customer and community care, responsible operations, and teammate empowerment.
• The company's executive compensation program is designed to reflect a pay-for-performance philosophy that aligns with the business's strategy and goals.
• The company's executive compensation program is designed to enhance both shortand long-term performance.

Negatives

• The company's cumulative adjusted EPS for the three-year period from January 1, 2022 through December 31, 2024, was below the target, resulting in no achievement of the PSUs granted in 2022.
• The company's cumulative adjusted EPS for the three-year period from January 1, 2022 through December 31, 2024, was below the target, resulting in no achievement of the PSUs granted in 2022.

Risks

• Cybersecurity and information security risks are a concern, requiring ongoing monitoring, mitigation, and threat assessment.
• Macroeconomic conditions and inflation could impact the company's financial performance.
• The company faces risks related to regulatory compliance and ethical supply chain management.
• The company faces risks related to regulatory compliance and ethical supply chain management.

Future Outlook

The company intends to continue to design its executive compensation arrangements to be consistent with its best interests and the interests of its shareholders.

Industry Context

The document provides insights into Owens & Minor's approach to executive compensation and governance within the healthcare industry, reflecting a focus on aligning executive pay with company performance and shareholder value, similar to practices observed in other publicly traded healthcare companies.

Comparison to Industry Standards

• The company generally targets the 50th percentile of its peer group and the relevant market as a reference point for positioning target total compensation for its executives.
• The company's peer group includes Baxter International Inc., Quest Diagnostics Incorporated, Boston Scientific Corporation, ResMed Inc., C.H. Robinson Worldwide, Inc., Select Medical Holdings Corporation, DENTSPLY SIRONA Inc., STERIS plc, Henry Schein, Inc., WESCO International, Inc., Hologic, Inc., Zimmer Biomet Holdings, Inc., and Patterson Companies, Inc.
• The company's executive compensation program is designed to reflect a pay-for-performance philosophy that aligns with the business's strategy and goals, both short and long-term, and pays for sustained performance, profitable growth, and achievement of results.

Management Changes

Stakeholder Impact

• Shareholders: Informed about company performance, governance, and executive compensation.
• Employees: Details on compensation, benefits, and company culture.
• Customers: Assurance of product quality and safety.
• Communities: Information on charitable contributions and community support.

Next Steps

• Shareholders to vote on proposals at the Annual Meeting on May 15, 2025.
• The Board and committees will continue to oversee risk management, ESG programs, and executive compensation practices.
• The company will continue to engage with shareholders through various outreach initiatives.

Key Dates

Keywords

executive compensation, annual meeting, corporate governance, director election, KPMG, ESG, proxy statement, shareholders, compensation, directors